ROVI held its Capital Markets Day where it explained to investors and analysts its strategic vision on the evolution of the business, its R&D plans and the main financial figures. Of particular note were the results obtained in the third quarter, with an increase of 24% in operating revenues and 23% in net profit.
Before investors or representatives of investment groups, Juan López-Belmonte, Chairman and CEO of ROVI, highlighted the main developments in 2022:
- The plan to launch Okedi® in Europe
- Development of a new plant for the self-supply of heparins in Huesca thanks to the collaboration with the agri-food group Costa Food Group and the meat group Càrniques Celrà.
- Extension of the collaboration with Moderna for the manufacture of RNA drugs for the next 10 years.
Javier López-Belmonte, vice-president and CFO of ROVI, has reviewed what will be the growth drivers for the coming year 2023:
- The launch and marketing of Okedi® in Europe
- The Heparin Division
- Distribution licensing agreements, such as Neparvis® and Volutsa®.
- Existing portfolio of speciality pharmaceuticals and new product distribution licences
- Agreement with Moderna
- New contracts and increased capacity in the area of third-party manufacturing
On the 2023 operating income growth rate forecast, although a decrease in the low second decade band is expected over 2022, growth is expected to be between 5% and 10% over 2021.
This will be accompanied by a high level of international investment, with the aim of reaching a presence in 110 countries in the coming years and a sales team specialising in the psychiatric area in Europe, as well as the consolidation of 10 manufacturing plants and the expansion of ROVI’s own key products (Bemiparin, a biosimilar of Enoxaparin, Risperidone ISM®, Letrozol ISM® and quarterly Risperidone ISM®) to 5.